Loading…
Loading…
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 974,881 shares of the company's stock, valued at approximately $17,509,000. Amylyx Pharmaceuticals comprises approximately 4.2% of Almitas
Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company's stock, valued at approximately $10,021,000. Deutsche Bank AG owned 0.50% of Amylyx Pharmaceuticals at the end of the most
Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (âAmylyxâ or the âCompanyâ) today announced the pricing of an upsized underwritten public offering of 14,090